Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 1.17% is 68% below its 4-year average of 3.69%, near the low end of its 4-year range (0.00%–5854.84%).
As of the fiscal period ended Tuesday, June 30, 2026. 38.28% below its 12-month average of 1.90%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 1.17%.
DEBT TO ASSETS RATIO
1.17%
DEBT TO ASSETS RATIO AVG TTM
1.90%
DEBT TO ASSETS RATIO AVG 3Y
3.20%
DEBT TO ASSETS RATIO AVG 5Y
N/A
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-38.28%
CURRENT VS 3Y AVG
-63.34%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 810 covered companies
CURRENT VS SECTOR MEDIAN
+1201.73%
vs the sector median at left
Bullfrog AI Holdings, Inc. Common Stock
Market Cap
$12.29M
Debt to Assets Ratio
1.17%
TTM Avg
1.90%
3Y Avg
3.20%
5Y Avg
N/A
Market Cap
$12.35M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$12.52M
Debt to Assets Ratio
0.30%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$12.82M
Debt to Assets Ratio
0.69%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$12.90M
Debt to Assets Ratio
0.04%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$11.58M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$11.56M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bullfrog AI Holdings, Inc. Common Stock (BFRG) | $12.29M | 1.17% | 1.90% | 3.20% | N/A |
| Lantern Pharma Inc. (LTRN)vs › | $12.35M | 0.00% | N/A | N/A | N/A |
| IRIDEX Corporation (IRIX)vs › | $12.12M | 0.15% | N/A | N/A | N/A |
| Dare Bioscience, Inc. (DARE)vs › | $12.52M | 0.30% | N/A | N/A | N/A |
| Cytosorbents Corporation (CTSO)vs › | $12.82M | 0.69% | N/A | N/A | N/A |
| Passage Bio, Inc. (PASG)vs › | $12.88M | 0.00% | N/A | N/A | N/A |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.90M | 0.04% | N/A | N/A | N/A |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $11.58M | 0.00% | N/A | N/A | N/A |
| Phio Pharmaceuticals Corp. (PHIO)vs › | $11.56M | 0.00% | N/A | N/A | N/A |
| Biofrontera Inc. (BFRI)vs › | $11.37M | 0.31% | N/A | N/A | N/A |
Debt/Assets
1.2%
Debt/Equity
0.01
Current Ratio
10.57
Interest Coverage
-1171.5x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 1.17% |
| 2026-03-31 | 2.42% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 2.06% |
| 2025-06-30 | 3.84% |
| 2025-03-31 | 4.02% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 3.74% |
| 2024-06-30 | 5.61% |
| 2024-03-31 | 6.63% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 5.06% |
| 2023-06-30 | 7.00% |
| 2023-03-31 | 10.10% |
| 2022-12-31 | 1964.36% |
| 2022-09-30 | 2270.96% |
| 2022-06-30 | 504.65% |
| 2021-12-31 | 5854.84% |
